A clean, vegan, science-led solution for comprehensive cardiovascular health. Reduchole 22® is derived from premium sugarcane wax and clinically proven to optimise the broader cardiometabolic network.
Reduchole 22® is a clinically proven, high-potency Policosanol extract derived from premium sugarcane wax — the most well-studied natural source of long-chain primary aliphatic alcohols for lipid profile management. Manufactured by Ingex Botanicals (P) Limited, India, the manufacturing arm of Ingex Germany GmbH, and supplied to European cardiovascular, cholesterol management and supplement brands.
Reduchole 22® addresses the need for a clean, vegan solution for comprehensive lipid management. Going beyond conventional cholesterol support, it provides a science-backed, multi-targeted approach to promote a balanced lipid profile and long-term cardiovascular resilience.
Backed by an 8-week, 120-subject randomised, double-blind, placebo-controlled clinical study at just 22 mg/day, Reduchole 22® is precision-standardised to ≥90% total fatty alcohols by GC, with an assured content of 60% octacosanol — the level of analytical rigour premium European nutraceutical brands demand.
Everything you need to know about this clinically proven Policosanol ingredient — origin, standardisation, science, and certifications.
Reduchole 22® is a natural Policosanol extract derived from premium sugarcane wax — the most established and well-studied source of long-chain fatty alcohols for cardiovascular and lipid management applications.
Precision-standardised to guarantee ≥90% total fatty alcohols by Gas Chromatography (GC), with an assured content of 60% octacosanol — ensuring batch-to-batch consistency and clinical-grade potency.
Backed by an 8-week, 120-subject randomised, double-blind, placebo-controlled clinical study at 22 mg/day showing significant improvements across Total Cholesterol, LDL, HDL and Triglycerides.
100% Vegan. Manufactured in NSF-GMP, HACCP, ISO 9001 certified facility. Kosher & HALAL certified. Fully EU-compliant with full batch documentation for European regulatory submissions.
Clinical validation at a low dose, precision GC standardisation, multi-targeted lipid action, and a vegan, EU-ready supply chain — the four foundations behind every Reduchole 22® batch.
8-Week, 120-Subject Trial
Randomised, double-blind, placebo-controlled at just 22 mg/day≥90% Total Fatty Alcohols
By Gas Chromatography (GC), with 60% assured Octacosanol content7-Alpha Hydroxylase & More
Improves cholesterol excretion markers for full-spectrum lipid modulation100% Plant-Based
Premium sugarcane wax source, EU-compliant, clean-label readyFrom consistent, certified quality and Rotterdam warehouse stock to full EU documentation, Reduchole 22® is built for European B2B nutraceutical, cardiovascular health and supplement brands.
Reduchole 22® addresses the global market need for a natural, clinically validated, vegan solution to support healthy cholesterol levels and full-spectrum cardiovascular health.
Whether you’re formulating capsules, tablets, softgels, gummies, or premium cardiovascular health blends, Reduchole 22® delivers clinical-grade efficacy with a clean-label, EU-compliant profile.
As dedicated Policosanol suppliers in Europe, we hold stock at our Rotterdam warehouse for fast, reliable delivery across the EU. No long lead times. Your order ships from the Netherlands.
Get a QuoteReduchole 22® is supplied as a clinically validated, precision-standardised Policosanol extract for the European supplement, cardiovascular health and functional nutraceutical markets. Custom specifications available on request.
| Grade / Form | Standardisation | Typical Application |
|---|---|---|
| Reduchole 22® Policosanol | ≥90% Total Fatty Alcohols by GC (60% Octacosanol) | Cardiovascular & cholesterol management capsules, tablets, softgels and premium lipid health formulas |
| Custom Grade | Available on Request | Bespoke to customer formulation specifications |
Reduchole 22® is supplied as a standardised powder form. Contact us for certificates of analysis, safety data sheets and technical specifications.
Reduchole 22® is backed by a randomised, double-blind, placebo-controlled clinical trial evaluating lipid profile management over 8 weeks.
120 subjects · 8 weeks · 22 mg/day Policosanol vs Placebo
A prospective, randomised, double-blind, placebo-controlled clinical trial conducted on 120 subjects over 8 weeks with a daily dose of 22 mg/day Reduchole 22®. The study evaluated four primary lipid endpoints: Total Cholesterol (TC), LDL cholesterol, HDL cholesterol, and Triglycerides across baseline, 4 weeks and 8 weeks.
The study also evaluated multi-targeted mechanistic markers including 7-Alpha hydroxylase activity and cholesterol excretion markers, providing mechanistic insight into the lipid-modulating action of Policosanol. Full study summary available for compliance and formulation teams on request.
Request Full Study SummaryTotal Cholesterol (mg/dL)
14.8% reduction in Total Cholesterol over 8 weeks, Reduchole 22® vs Placebo
LDL Cholesterol (mg/dL)
26.5% reduction in LDL over 8 weeks, Reduchole 22® vs Placebo
Common questions from nutraceutical, cardiovascular health and supplement brands in Europe about Reduchole 22® Policosanol.
Request a sample, bulk quote, or technical documentation for Reduchole 22® Policosanol. Our team responds within one business day.
Or write to us at: enquiry@ingexgermany.de